Sudden unexplained death in psychiatric in-patients

LOUIS APPLEBY, SIMON THOMAS, NICOL FERRIER, GLYN LEWIS, JENNY SHAW and TIM AMOS

Reports of sudden death in people with mental illness who are taking antipsychotic medication have been a source of public and professional controversy for three decades. Psychiatric patients are at increased risk of death from a number of natural causes, including cardiovascular disease (Sims & Prior, 1980; Baxter, 1996; Hansen et al, 1997; Harris & Barracough, 1998; Ruschena et al, 1998). Because many sudden deaths are the result of coronary artery disease, an increase in sudden deaths would be expected by this mechanism alone. However, cases of sudden death in young patients and recent evidence in schizophrenia of a high rate of sudden death without explanatory post-mortem findings suggest that factors other than coronary artery disease are contributory (Ruschena et al, 1998). In 1997 a report by an expert committee convened by the Royal College of Psychiatrists recommended a large-scale systematic study of the relationship between psychotropic drugs and sudden death (Royal College of Psychiatrists, 1997). Such a study has now begun; psychiatrists throughout England and Wales will be asked to take part and one purpose of this paper is to explain how it will be conducted.

CARDIAC EFFECTS OF ANTIPSychOTIC DRUGS

The mechanism by which antipsychotic drugs may cause sudden death is by inducing cardiac arrhythmias, because they are known to disturb normal cardiac electrophysiology, resulting in electrocardiogram (ECG) changes. Their actions are similar to those of the anti-arrhythmic drug quinidine, and include sodium channel blockade and delay to ventricular repolarisation (Arita & Surawicz, 1973). Severe sodium channel blockade may be clinically important after poisoning with antipsychotic drugs and appears on the ECG as broadening of the QRS complex, reflecting reduced conduction velocity through the specialist conducting tissue in the bundle of His. Delayed ventricular repolarisation is probably more important because it can be detected after therapeutic doses of antipsychotic drugs. It appears on the ECG as abnormalities of the T wave, prominent U waves and/or prolongation of the QT interval. This is the interval between the onset of ventricular depolarisation and the end of ventricular repolarisation. The QT interval shortens with increasing heart rate and is often adjusted for this to produce a corrected QT interval, or QTc (Thomas, 1994).

These changes might, in extreme cases or in susceptible individuals, lead to malignant ventricular arrhythmias, particularly a multifocal ventricular tachycardia termed torsade de pointes. This is usually self-limiting, causing dizziness or syncope, but may generate into ventricular fibrillation and cause sudden death (Thomas, 1994). The importance of this mechanism has been highlighted recently by the withdrawal of sertindole, an atypical antipsychotic, because of its propensity to cause QT interval prolongation, and following reports of arrhythmias and sudden deaths (Committee on Safety of Medicines, 1999). Thoridizine, which has often been implicated in sudden cardiac death or cardiac arrhythmias, also causes concentration-related QT interval prolongation (Hartigan-Go et al, 1996). Other psychotropic drugs that have this effect include tricyclic antidepressants and lithium (Thomas, 1994) and this may be particularly important when these drugs are used in combination with antipsychotics (Heiman, 1977). The repolarisation delay is a dose-related phenomenon and is therefore particularly common after drug overdose, with high-dose therapy and in the presence of drug interactions or diseases that delay the elimination of these agents.

There have been few systematic studies to determine the frequency of ECG abnormalities in patients taking antipsychotic drugs. Early research suggested that such abnormalities, including T wave changes, are present in 25–50% of those receiving phenothiazines, ECG changes being more common with thioridazine than chlorpromazine (Ban & St-Jean, 1965; Alvarez-Mena & Frank, 1973). The prevalence of T wave changes appears to increase with the dose of antipsychotic drug (Axelsson & Apstenstrom, 1982). These studies did not measure QT intervals but more recent research suggests that the QTc interval is prolonged in only a small proportion of patients. For example, in a recent study of 268 mixed psychiatric patients, 6% had a QTc interval above a widely accepted upper limit of 440 ms. No patients were found with a QTc interval of more than 500 ms, a threshold below which torsade de pointes is unlikely. The QTc prolongation was more prevalent in female and older patients and in those receiving thioridazine, and the latter effect was independent of age (Reilly et al, 2000). This finding is consistent with the apparently greater toxicity of thioridazine than other antipsychotic drugs when taken in overdose (Buckley et al, 1995). A study in Finland has suggested that a disproportion number of sudden deaths are in psychiatric patients taking this drug (Mehtonen et al, 1991).

NON-DRUG RISK FACTORS

Little specific evidence exists on the patient factors that might predispose to cardiac arrhythmias in the presence of antipsychotic drugs, but these are likely to be the same as those found with quinidine. The presence of underlying cardiac disease is particularly important. Some patients have QTc prolongation in the absence of drug treatment, either because of acquired cardiac disease or as a hereditary phenomenon, and are at particular risk. Other likely risk factors are previous arrhythmias, impaired left ventricular function, concurrent digoxin therapy and hypokalaemia from any cause, including diuretic treatment (Nguyen et al, 1986; Minardo et al, 1988; Slater et al, 1988; Pratt et al, 1989).

Important questions about sudden death in psychiatric patients therefore remain. What is the contribution of underlying physical illness? What part is played by misuse of illicit drugs, and by alcohol and tobacco? Do restraint and
physiological arousal increase risk? Even
the number of cases is unknown. Then
there is the central issue of the role of anti-
psychotic drugs. Are they, after all, a cause
of sudden death? If so, which drugs are re-
sponsible? Is risk linked to high dosage or
polypharmacy?

NEW STUDY

The new study, funded by the Department of
Health, aims to answer these questions and
to make recommendations for clinical prac-
tice. It is firstly a survey of the clinical
circumstances in which sudden unexpected
deaths occur in psychiatric in-patients. This
part of the study is analogous to the
National Confidential Inquiry into Suicide
and Homicide by People with Mental Ill-
ness (Appleby et al, 1997), and the three
collaborating centres are Manchester (where
the Inquiry is based), Newcastle-upon-Tyne and
Cardiff. Secondly, it is a case–control
study from which risk factors can be identi-
fied and their impact quantified. The con-
trols are matched in-patients who were alive
at the time of death of the correspond-
ing case.

Both cases and controls will be taken
from the National Health Service contract
data-set on hospital in-patients, to which
all hospital trusts contribute. The initial
sample of potential cases will consist of
everyone who has died as a psychiatric
in-patient. The research team will write to
the responsible consultant, asking him or
her to complete a questionnaire about the
patient. The first section of the question-
aire determines whether the patient’s
death satisfies a definition of sudden unex-
plained death; if it does, there are further
sections to complete on, in particular, clin-
ical history and treatment. The controls are
selected randomly from in-patients nation-
ally, so it is unlikely that both case and
control will come from the same hospital –
otherwise hospital policies on care and
treatment could make it hard to find differ-
ences. The questionnaire for controls is the
same as for cases. An important feature of
the study is that the research team will not
know the identity of either cases or con-
trols; they will be known only by their
hospital numbers.

The expected frequency of sudden un-
explained death is such that few psychia-
trists will be asked to complete more than
one questionnaire. Most will not be asked
at all. The response rate in the National
Confidential Inquiry is 92% (Appleby et
al., 1999). The success of the new study will
similarly depend on the cooperation of busy
clinicians; a similar response will help us
address one of the most sensitive questions
facing clinical practice.

REFERENCES

Alvaro-Mano, S. & Frank, M. (1972) Pheno- 
thiazine-induced T-wave abnormalities. Effects of overnight
fasting. Journal of the American Medical Association, 224:
730–733.

Confidential Inquiry into Suicide and Homicide by People with Mental Illness. British Journal of Psychiatry, 170:
101–102.

Appleby, L., Shaw, J. & Amos, T. (1999) Suicide within 12 months of contact with mental health services: national clinical

Arita, M. & Surawicz, B. (1973) Electrophysiologic effects
of phenothiazines on canine cardiac fibers. Journal of Phar-
macology and Experimental Therapeutics, 184: 619–630.


Ban, T. A. & St-Jean, A. (1965) Electrocardiographic changes
induced by phenothiazine drugs. American Heart

772–779.

Cardioxicity more common in thioridazine overdose than
other neuroleptics. Journal of Toxicology – Clinical Toxicology, 33: 199–204.

Committee on Safety of Medicines (1999) Suspension of availability of sertindole (Serdolect) due to reports of sudden cardiac death. Current Problems in
Pharmacovigilance, 25: 1.


Hartigan-Ga, K., Bateman, D. N., Nyberg, G., et al
Pharmacology and Therapeutics, 60: 543–553.

Heiman, E. M. (1977) Cardiac toxicity with
thioridazine—Tricyclic antidepressant combination. Journal of Nervous and Mental Disease, 165: 139–143.

Total mortality in people admitted to a psychiatric

Mehtonen, O., Aranko, K., Malkonen, L., et al
(1991) Survey of sudden death associated with the use
of antipsychotic or antidepressant drugs: 49 cases in

(1988) Clinical characteristics of patients with ventricular
fibrillation during anti-arrhythmic drug therapy. New
England Journal of Medicine, 319: 257–262.

Polymorphous VT: clinical characterisation, therapy and

Pratt, C. M., Eaton, C., Francis, M., et al
(1989) The inverse relationship between baseline left ventricular ejection fraction and outcome of anti-arrhythmic
therapy: a dangerous imbalance in the risk–benefit


Royal College of Psychiatrists (1997) The associated
London: Royal College of Psychiatrists.

Ruschens, D., Mulhen, P. E., Burgess, P., et al

Sims, A. C. P. & Prior, M. P. (1980) Arteriosclerosis-
related deaths in severe neurosis. Comprehensive

Slater, W., Lampert, S., Podrid, P. T., et al
(1988) Clinical predictors of arrhythmic worsening by anti-

Thomas, S. H. L. (1994) Drugs, QT interval
abnormalities and ventricular arrhythmias. Adverse Drug

Correspondence: Professor Louis Appleby, National Confidential Inquiry into Suicide and Homicide by People with Mental Illness, School of Psychiatry and Behavioural Sciences, Withington Hospital, West Didsbury, Manchester: Simon Thomas, MD, Wolfson Unit of Clinical Pharmacology, Claremont Place, Newcastle-upon-Tyne; NICOL FERRIER, MD, School of Neurosciences, Division of Psychiatry, The Royal Victoria Infirmary, Newcastle-upon-Tyne; GLYN LEWIS, FRCPsych, Department of Psychological Medicine, University Hospital of Wales, College of Medicine, Heath Park, Cardiff

(First received 14 December 1999, accepted 17 December 1999)
Sudden unexplained death in psychiatric in-patients
LOUIS APPLEBY, JENNY SHAW, TIM AMOS, SIMON THOMAS, NICOL FERRIER and GLYN LEWIS
BJP 2000, 176:405-406.
Access the most recent version at DOI: 10.1192/bjp.176.5.405

References
This article cites 20 articles, 8 of which you can access for free at:
http://bjp.rcpsych.org/content/176/5/405#BIBL

Reprints/permissions
To obtain reprints or permission to reproduce material from this paper, please write to permissions@rcpsych.ac.uk

You can respond to this article at
/letters/submit/bjprcpsych;176/5/405

Downloaded from
http://bjp.rcpsych.org/ on May 2, 2017
Published by The Royal College of Psychiatrists

To subscribe to The British Journal of Psychiatry go to:
http://bjp.rcpsych.org/site/subscriptions/